Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRANDATE HCT vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TRANDATE HCT is a combination of labetalol, a non-selective beta-blocker with selective alpha-1 blocking activity, and hydrochlorothiazide, a thiazide diuretic. Labetalol reduces peripheral vascular resistance via alpha-1 blockade and decreases heart rate and cardiac output via beta-blockade. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, promoting diuresis and reducing plasma volume.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Treatment of hypertension,Management of hypertensive urgency (off-label)
Hypertension
Oral: 100 mg labetalol/25 mg hydrochlorothiazide twice daily, titrated based on blood pressure response; maximum 1200 mg labetalol/300 mg hydrochlorothiazide daily.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
Labetalol: terminal elimination half-life is 6-8 hours (range 3-16 hours) consistent with twice-daily dosing. Hydrochlorothiazide: terminal half-life 9-10 hours (range 6-15 hours), prolonged in renal impairment.
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Labetalol is extensively metabolized primarily via glucuronidation (direct conjugation) and minor CYP2D6-mediated oxidation to an inactive metabolite. Hydrochlorothiazide is not metabolized; it is excreted unchanged in urine.
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Labetalol is primarily excreted in urine as unchanged drug (approximately 55-60%) and as glucuronide conjugates. About 12-27% is excreted in feces via biliary elimination. Hydrochlorothiazide is excreted unchanged in urine (≥95%) via renal tubular secretion. Total renal elimination of labetalol: ~55-60% unchanged; HCTZ: ~95% unchanged.
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
Labetalol: ~50% bound to albumin. Hydrochlorothiazide: ~40-68% bound to albumin and alpha-1-acid glycoprotein.
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
Labetalol: Vd 3-16 L/kg (mean 11 L/kg), indicating extensive tissue distribution. Hydrochlorothiazide: Vd 0.8-1.5 L/kg (mean 1 L/kg), limited distribution.
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Labetalol: oral bioavailability is 25-40% due to extensive first-pass metabolism. Hydrochlorothiazide: oral bioavailability is 65-75% (fasted).
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
GFR 30-90 m L/min: No adjustment. GFR <30 m L/min: Contraindicated due to hydrochlorothiazide component.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Child-Pugh A: Use with caution; reduce labetalol dose. Child-Pugh B or C: Contraindicated due to extensive hepatic metabolism of labetalol.
Child-Pugh Class B or C: contraindicated; use not recommended.
Not recommended; safety and efficacy not established for labetalol/hydrochlorothiazide combination.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Start at lowest dose (100/25 mg daily); titrate slowly due to increased risk of hypotension and electrolyte imbalance.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
None
None
Beta-blocker withdrawal: abrupt discontinuation may exacerbate angina or precipitate myocardial infarction in patients with coronary artery disease. Bronchospasm: avoid in patients with bronchial asthma or COPD. Heart failure: caution in patients with decompensated heart failure; may precipitate worsening. Peripheral vascular disease: may worsen symptoms. Hepatic impairment: labetalol is hepatically metabolized; use caution. Renal impairment: hydrochlorothiazide may be ineffective with Cr Cl <30 m L/min. Electrolyte disturbances: monitor potassium, sodium, magnesium; risk of hypokalemia, hyponatremia, hypomagnesemia. Hyperuricemia: can precipitate gout. Photosensitivity: with hydrochlorothiazide. Exacerbation of systemic lupus erythematosus: reported with thiazides. DM: beta-blockers may mask hypoglycemia. Surgery: withdrawal before elective surgery recommended.
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
Absolute: sinus bradycardia, heart block greater than first degree, cardiogenic shock, decompensated heart failure, bronchial asthma, hypersensitivity to labetalol, hydrochlorothiazide, or sulfonamide-derived drugs, anuria. Relative: diabetes mellitus, hyperthyroidism, pheochromocytoma (labetalol may paradoxically elevate blood pressure), severe renal impairment (Cr Cl <30 m L/min for thiazide efficacy).
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
Avoid tyramine-rich foods (aged cheese, cured meats, fermented soy products) due to potential hypertensive crises. Limit caffeine intake; may increase heart rate. Avoid excessive potassium-rich foods or supplements unless monitored due to hydrochlorothiazide's potassium-wasting effect. Take with food to reduce GI upset.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
First trimester: No clear association with major malformations in limited human data; labetalol crosses placenta. Second/third trimester: Potential fetal bradycardia, hypotension, hypoglycemia, and respiratory depression; intrauterine growth restriction reported with chronic use.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
Labetalol is excreted into breast milk in low amounts (M/P ratio ~0.6-0.8); generally considered compatible with breastfeeding; monitor infant for bradycardia and hypotension.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
No standard dose adjustment required; however, pregnancy may alter labetalol pharmacokinetics (increased clearance, decreased half-life) potentially necessitating dose titration based on clinical response.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
Trandate HCT combines labetalol (alpha/beta blocker) and hydrochlorothiazide. Monitor heart rate, blood pressure, and electrolytes. Avoid in asthma, COPD, bradycardia, heart block, and anuria. Taper if discontinuing. May mask hypoglycemia in diabetics. Can cause orthostatic hypotension; dose at bedtime initially.
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
Take exactly as prescribed, usually once daily, with or without food.,Do not stop suddenly; tapering is necessary to avoid rebound hypertension.,May cause dizziness or lightheadedness; rise slowly from sitting or lying.,Avoid alcohol; it can worsen dizziness and side effects.,Inform your doctor if you experience slow heartbeat, fainting, swelling of feet/ankles, or unusual weight gain.,May cause photosensitivity; use sunscreen and protective clothing.,Monitor blood pressure regularly at home.
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRANDATE HCT vs ALDORIL D30, answered by our medical review team.
TRANDATE HCT is a Antihypertensive Combination that works by TRANDATE HCT is a combination of labetalol, a non-selective beta-blocker with selective alpha-1 blocking activity, and hydrochlorothiazide, a thiazide diuretic. Labetalol reduces peripheral vascular resistance via alpha-1 blockade and decreases heart rate and cardiac output via beta-blockade. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, promoting diuresis and reducing plasma volume.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRANDATE HCT and ALDORIL D30 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRANDATE HCT is: Oral: 100 mg labetalol/25 mg hydrochlorothiazide twice daily, titrated based on blood pressure response; maximum 1200 mg labetalol/300 mg hydrochlorothiazide daily.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRANDATE HCT and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRANDATE HCT is classified as Category C. First trimester: No clear association with major malformations in limited human data; labetalol crosses placenta. Second/third trimester: Potential fetal bradycardia, hypotension, . ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.